研究单位：[1]Sun Yat-sen University[2]Chinese Southwest Oncology Group[3]Fujian Provincial Cancer Hospital,Fuzhou,Fujian,China,350014[4]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510060[5]The First Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,China,510080[6]Guangxi Cancer Hospital,Nanning,Guangxi,China,530021[7]Union Hospital,Tongji Medical College of Huazhong University of Science ＆ Technology,Wuhan,Hubei,China,430022[8]Tongji Hospital,Tongji Medical College of Huazhong University of Science ＆ Technology,Wuhan,Hubei,China,430030[9]Jiangsu Cancer Hospital,Nanjing,Jiangsu,China,210000[10]Fudan University Shanghai Cancer Center,Shanghai,Shanghai,China,200032[11]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610047[12]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022
研究目的：
This is a Phase Ⅲ randomized, controlled, multi-center, trial comparing cisplatin plus docetaxel to cetuximab, cisplatin, and docetaxel induction chemotherapy followed by concurrent chemoradiation in previously untreated patients metastatic nasopharyngeal carcinoma (mNPC) to determine whether the addition of cetuximab to induction chemotherapy and chemoradiation could improve therapeutic efficacy in mNPC, and investigate predictive and prognostic factors for mNPC.
